Millennium Management
SABS icon

Millennium Management’s SAB Biotherapeutics SABS Stock Holding History

Millennium Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Buy
3,032,697
+2,708,607
+836% +$10.8M ﹤0.01% 2036
2025
Q4 		$1.21M Buy
+324,090
New +$1.07M ﹤0.01% 4356
2025
Q2 		– Sell
-16,351
Closed -$22.1K – 6274
2025
Q1 		$22.1K Sell
16,351
-13,060
-44% -$29.9K ﹤0.01% 5622
2024
Q4 		$112K Sell
29,411
-22,535
-43% -$74K ﹤0.01% 5461
2024
Q3 		$140K Sell
51,946
-838
-2% -$2.32K ﹤0.01% 5526
2024
Q2 		$164K Sell
52,784
-1,266
-2% -$4.64K ﹤0.01% 5211
2024
Q1 		$245K Buy
+54,050
New +$298K ﹤0.01% 5258
2022
Q4 		– Sell
-3,855
Closed -$27K – 6985
2022
Q3 		$27K Sell
3,855
-2,567
-40% -$25.5K ﹤0.01% 6377
2022
Q2 		$93K Buy
+6,422
New +$135K ﹤0.01% 5967
2021
Q4 		– Sell
-19,131
Closed -$1.93M – 7311
2021
Q3 		$1.93M Buy
19,131
+15,465
+422% +$1.54M ﹤0.01% 3970
2021
Q2 		$365K Buy
+3,666
New +$364K ﹤0.01% 5562

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM

Millennium Management's SABS Position: Q1 2026 in Review

Millennium Management increased its SAB Biotherapeutics (SABS) stake by 836% in Q1 2026, buying an estimated $10.8M and bringing the position to 3,032,697 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

Millennium Management first reported a position in SABS in Q2 2021 and has held it in 11 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Millennium Management held 3,032,697 shares of SAB Biotherapeutics worth $11.6M as of Q1 2026.
  • Millennium Management bought 2,708,607 SAB Biotherapeutics shares in Q1 2026, an estimated $10.8M.
  • SAB Biotherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2036 holding.
  • Millennium Management first reported a position in SAB Biotherapeutics in Q2 2021 and has held it in 11 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.